Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 2
Submit an article Journal homepage
16
Views
3
CrossRef citations to date
0
Altmetric
Research

Review Anti-infectives: Tuberculosis: Current status and recent developments in diagnostics, drugs and vaccines

Ken Duncan Glaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY
Pages 175-185 | Published online: 29 Feb 2008

References to Primary Literature

  • SNIDER DE Jr., RAVIGLIONE M, KOCHI A: Global burden of tuberculosis. In: Tuberculosis: Pathogenesis, Protection,and Control, Bloom BR (Ed.) ASM Press, Washington pp 3–11 (1994). Concise review of latest data on tuberculosis problem world-wide. Many references to Bloom's book follow: it is a very thorough, up-to-date review of the tuberculosis field.
  • MURRAY CJL, STYBLO K, ROUILLON A: Tuberculosis in developing countries: burden, intervention and cost. Bull. Int. Union Tuberc. Lung Dis. (1990) 65:6–24.
  • KOCHI A: The global tuberculosis situation and the new control strategy of the World Health Organisation. Tubercle (1991) 72:1–6.
  • BLOOM BR, MURRAY CJL: Tuberculosis: commentary on do*a reemergent killer. Science (1992) 257:1055-1064.Comprehensive explanation and evaluation of the factors underlying the increasing tuberculosis problem, with emphasis on the situation in the USA.
  • RYAN F: Tuberculosis: The greatest story never told (1992) Swift Publishers, England. A fascinating account of the human side of how the battle against tuberculosis was won - and lost.
  • HOPEWELL PC: Overview of clinical tuberculosis. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed) ASM Press, Washington pp 25–46 (1994).
  • NATIONAL TUBERCULOSIS INSTITUTE, BANGALORE: Tu-berculosis in a rural population in South India: a five-year epitlemiologicalstudy. Bull. World Health Org. (1974) 51:473–488.
  • BARNES PF, MODLIN ItL, ELLNER JJ: T-cell responses andcytokines. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 417–435 (1994).
  • ROOK GAW, BLOOM BR: Mechanisms of pathogenesisin tuberculosis. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington PP 485–501 (1994).
  • NOORDEEN SK: The epidemiology of leprosy. In: Leprosy, Hastings RC, Opromolla DVA (Eds.) pp29–45 (1994).
  • NUNN PP, MCADAM KPWJ: Mycobacterial infections and AIDS. Brit. Med. Bull. (1988) 44:801–813.
  • WRIGHT PW, WALLACE RJ: Nontuberculous mycobacte-ria with and without mv infection. In: Tuberculosis: Current Concepts and Treatment, Friedman LN (Ed.) CRC Press, Boca Raton pp183–206 (1994).
  • BARNES PF, BLOCH AB, DAVIDSON PT, SNIDER DE Jr.: Tuberculosis in patients with human immunodefi-ciency virus infection. N. Engl. J. Med. (1991) 324:1644–1650.
  • SELWYN PA, HARTEL D, LEWIS VA, SCHOENBAUM EE, VERMUND SH, KLEIN RS, WALKER AT, FRIEDLAND GH: A prospective study of the risk of tuberculosis among Intravenous drug users with human immunodeficiency virus infection. New Engl. J. Med. (1991) 320:545–550.
  • STANFORD, JL, GRANGE, JM, POZNIAK A: Is Africa lost?Lancet (1991) 338:557–558.
  • DE COCK KM: Impact of interaction with IHV. In: Tuber-culosis: Back to the Future, Porter JDH, McAdam ICPWJ (Eds.) John Wiley and Sons, Chichester pp35–49 (1994).
  • LUCAS S, NELSON AM: Pathogenesis of tuberculosis in human Immunodeficiency virus-infected people. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 503–513 (1994).
  • SMALL PM, VAN EMBDEN JDA: Molecular epidemiology of tuberculosis. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington PP 569–582 (1994).
  • CYNAMON MH, KLEMENS SP: Chemotherapeutic agents for mycobacterial infections. In: Tuberculosis: Current Concepts and Treatment, Freidman LN (Ed.) CRC Press, Boca Raton pp237–57 (1994). Contains detailed information on the properties of all the agents in use today against tuberculosis.
  • JACOBS RF: Multiple-drug-resistant tuberculosis. Clin. Inf. Dis. (1994) 19:1–10.
  • SNIDER D Jr., ROPER WL: The new tuberculosis. New Engl. J. Med. (1991) 326:703–705.
  • O'BRIEN R: Preventive therapy for tuberculosis. In: Tu-berculosis: Back to the Future, Porter JDH, McAdam ICPWJ (Eds.), John Wiley and Sons, Chichester pp151–166 (1994).
  • FINE PEM: Immunities in and to tuberculosis: implications for pathogenesis and vaccination. In: Tuberculosis:Back to the Future, Porter JDH, McAdam KPWJ (Eds.), John Wiley and Sons, Chichester pp53–74 (1994).
  • BLOOM BR, FINE PEM: The BCG experience: implications for future vaccines against tuberculosis. In: Tuberculosis:Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 531–557 (1994). Explanation of the issues involved in developing a new vaccine against tuberculosis.
  • HOUSTON S, FANNING A: Current and potential treatment of tuberculosis. Drugs (1994) 48:689–708.
  • YOUNG DB, DUNCAN K: Prospects for new Interventions in the treatment and prevention of mycobacterial disease. Annu. Rev. Microbiol. (1995) 49:641-673. Thorough review of the prospects for both new drugs and new vaccines against tuberculosis.
  • ORME IM: Prospects for new vaccines against tuberculosis. Trends Microb. (1995) 3:401–404.
  • Harnessing the profit motive. Lancet (1995) 345:1189–1190.
  • JACOBS WR Jr., BARLETTA RG, UDANI R, CHAN J, KALICUTG, SOSNE G, KIESER T, SARKIS GJ, HATFULL GF, BLOOM BR: Rapid assessment of drug susceptibilities of Myco-bacterium tuberculosis by means of ludferase reporter phages. Science (1993) 260:819-822. Imaginative solution to the very real problem of rapidly diagnosing tuberculosis.
  • ROBERTS GD, GOODMAN NL, HELMS L, LARSH HW, LINDNER TH, McCLATCHY JK, McGINNIS MR, SIDDIQI SH, WRIGHT P: Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug suscep-tibility testing of Mycobacterium tuberculosis from acid-fast smear-positive spedmens. I Clin. Microbiol. (1983) 18:689–696.
  • ASIITEICAR DR, FERNANDES F, KHADSE GG, SHLRODICARMVN: A rapid method for the evaluation of new antitu-berculous agents. Chemotherapy (1987) 33:22–27.
  • COOKSEY RC, CRAWFORD JT, JACOBS WR Jr., SHINNICKTM: A rapid method for screening antimicrobial activi-ties against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. (1993) 37:1348–1352.
  • ANDREW PW, ROBERTS IS: Construction of a biolumines-cent mycobacterium and its use for assay of antimyco-bacterial agents. J. Clin. Microbiol. (1993) 31:2251–2254.
  • CHUNG GAC, AKTAR Z, JACKSON S, DUNCAN K: High throughput screen for detecting antimycobacterial agents. Antimicrob . Agents Chemother. (1995) 39:2235–2238.
  • MCNEIL MR BRENNAN PJ: Structure, function and bio-genesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resis-tance; some thoughts and possibilities arising from recent structural information. Res. Microbiol. (1991) 142:397–403.
  • MINNIKEN DE: Lipids: complex lipids, their chemistry, biosynthesis and roles. In: The Biology of the Mycobacteria Vol I, Ratledge c, Stanford J (Eds.), pp 95–184 (1982).
  • BRENNAN PJ, DRAPER P: Uhrastructure of Mycobac-terium tuberculosis. In: Tuberculosis: Pathogenesis, Protec-tion, and Control, Bloom BR (Ed.) ASM Press, Washington pp 271–284 (1994).
  • BESRA GS, CHATTERJEE D: Lipids and carbohydrates ofMycobacterium tuberculosis. In: Tuberculosis: Patho-genesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 285–306 (1994).
  • BESRA GS, SLEVERT T, LEE RE, SLAYDEN RA, BRENNAN PJ,TAKAYAMA K: Identification of the apparent carrier in mycolic add synthesis. Proc. Natl. Acad. Sci. (1995) 91;12735–12739.
  • YUAN Y, LEE RE, BESRA GS, BELISLE JT, BARRY CE: Identification of a gene involved in the biosynthesis of cyclopropanated mycolic adds in Mycobacterium tu-berculosis. Proc. Natl. Acad. Sci. (1995) 92:6630–6634.
  • WOLUCKA BA, McNEIL MR, DE HOFFMANN E, CHOJNACKT, BRENNAN PJ: Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and Its relation to the mode of action of ethambutol on mycobacteria. J. Biol. Chem. (1994) 269: 23328–23335.
  • SCHERMAN M, WESTON A, DUNCAN K, WHITTINGTON A,UPTON R, DENG L, COMBER R, FRIEDRICH JD, McNEIL M: Biosynthetic origin of mycobacterial cell wall arabino-syl residues. J. Bacteriol. (1995) 177:7125–7130.
  • MIKUSOVA K, SLAYDEN RA, BESRA GS, BRENNAN PJ: Biogenesis of the mycobacterial cell wall and the site of action of ethambutoL Antimicrob. Agents Chemother. (1995) 39:2484–2489.
  • WOLUCKA BA, DE HOFFMANN E: The presence of -D-mo-nophosphodecaprenol in mycobacteria. J. Biol. Chem. (1995) 270:20151–20155.
  • WESTON A, NASSAU P, MONSEY D, BROWN RE, McNEILMR, DUNCAN K: The biosynthetic origin of the myco-bacterial cell wall galactosyl residues. Manuscript in preparation.
  • CIRRI° JD; WEISBROD TR; BANERJEE A; BLOOM BR; JACOBS WR Jr: Genetic determination of the meso-diami-nopimelate biosynthetic pathway of mycobacteria. J. Bacteriol. (1994) 176:4424–4429.
  • FALKINHAM III JO, CRAWFORD JT: Plasmids. In: Tubercu-losis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 185–198 (1994).
  • MCADAM RA, GU1LHOT C, GICQUEL B: Transposition in mycobacteria. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 199–216 (1994).
  • COLSTON MJ, DAVIS EO: Homologous recombination,DNA repair and mycobacterial recA genes. In: Tubercu-losis: Pathogenesis, Protection, and Control, Bloom BR (Ed.) ASM Press, Washington pp 217–226 (1994).
  • BROGDEN RN, FITTON A: Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 47:983–1009.
  • SAITO H, TOMIOKA H, SATO K, EMORI M, YAMANE T,YAMASHITA K, HOSOE K, HIDAKA T: In vitro antimyco-bacterial activities of newly synthesised benzoxazinori-famycins. Antimicrob. Agents Cbemother. (1991) 35:542–547.
  • ICL.EMENS SP, GROSSI MA, CYNAMON MH: Activity ofKRM-1648, a new benzosazinorifamycin, against Myco-bacterium tuberculosis in a murine modeL Antimicrob. Agents Chemother. (1994) 35:2245–2248.
  • SAITO H, TOMIOKA H, SATO K, KAWAHARA S, HIDAKA T, DEKI0 S: Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium infection In mice. Tub. Lung Dis. (1995) 67:51–58.
  • HIRATA T, SAITO H, TOMIOKA H, SATO K, JIDOI J, HOSOE K, HIDAKA T: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648. Antimicrob. Agents Cbemother. (1995) 39:2295–2303.
  • SLEE AM, WUONOLA MA, McRIPLEY RJ, ZAJAC I, ZAWADAMJ, BARTHOLOMEW PT, GREGORY WA, FORBES M: Oxa-zolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP-105 and DuP-721. Antimicrob. Agents Chemother. (1987) 31:1791–1797.
  • WONG CS, PALMER GS, CYNAMON MH: In vitro suscep-tibilityofMycobacterium tuberculosis,Mycobacterium bovis, andMycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid. J. An-timicrob. Chemother. (1988) 22:863–866.
  • STANFORD JL, BAHR GM, ROOK GA, SHAABAN MA, CHUGH TD, GABRIEL M, AL-SHIMALI B, SIDDIQUI Z, GHARDINI F, SHAHIN A, BEHBEHANI K: Immunotherapy with Mycobacterium vaccae as an adjunct to chemo-therapy in the treatment of pulmonary tuberculosis. Tubercle (1990) 71:87–93.
  • ROOK GA, ONYEBUJOH P, WILKINS E, AL ATTIYAH R, BAHR G, CORRAH T, HERNANDEZ H, STANFORD JL: A longitudinal study of per cent agalactosyl IgG in tuber-culosis patient receiving chemotherapy, with or with-out Immunotherapy. Immunology (1994) 81:149–154.
  • STANFORD JL, STANFORD CA: Immunotherapy of tuber-culosis with Mycobacterium vaccae NCTC 11659. Im-munobiol. (1994) 191:555–563.
  • ONYEBUJOH PC, ABDULMUMINI T, ROBINSON S, ROOKGA, STANFORD JL: Immunotherapy with Mycobac-terium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir. Med. (1995) 89:199–207.
  • HORWITZ MA, LEE BWE, DIUON BJ, HARTH G: Protective immunity against tuberculosis induced by vaccination with major extracelhuar proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. (1995) 92:1530-1534. Thorough evaluation of promising subunit vaccine candidates.
  • ARRUDA S, BOMFIM G, KNIGHTS R, HUIMA-BYRON T, RILEY LW: Cloning of anM. tuberculosis DNA fragment associated with entry and survival inside cells. Science (1993) 261:1454–1457.
  • STOVER CK, DE LA CRUZ VF, FUERST TR, BURLEIN JE, BENSON LA, BENNETT LT, BANSAL GP, YOUNG JF, LEE MH, HATFULL GF, SNAPPER SB, BARLETTA RG, JACOBS WR Jr., BLOOM BR: New use of BCG for recombinant vaccines. Nature (1991) 351:456–460.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.